President Trump’s choice to lead the FDA faced some questions, but not many, about drug pricing, according to various press reports about the Senate committee hearing Thursday regarding the nomination of Stephen Hahn, MD, FASTRO, the chief medical officer of MD Anderson Cancer Center.
President Trump’s choice to lead the FDA faced some questions, but not many, about drug pricing, according to various press reports about the Senate committee hearing Thursday regarding the nomination of Stephen Hahn, MD, FASTRO, the chief medical officer of MD Anderson Cancer Center.
The issue of vaping, and whether he supports a ban on flavored products, was the primary focus; he demurred from specifics, saying he would defer to the White House, where a policy is under review.
In prepared testimony before the Senate’s Committee on Health, Education Labor and Pensions (HELP), Hahn said that, if confirmed, “I promise to be guided by the core values of integrity and transparency, and I promise to put the interests of the American people first.” He also stressed his scientific background and said he respected Congress.
Also on Wednesday, the Biosimilars Forum released a statement stressing how previous FDA commissioners—most notably Scott Gottlieb, MD—promoted biosimilars.
Past leaders “have recognized the urgent need for educating stakeholders and accelerating biosimilar uptake, given that patients and the US health care system at large could save up to $150 billion over the next decade with increased biosimilar use. It is critical that the FDA continue combating misinformation and anti-competitive practices surrounding biosimilars, as well as reforming regulatory processes to allow for increased competition in the market,” the forum said.
Eleven of the 25 approved biosimilars are currently on the market, noted the forum, which is supporting various pieces of legislation to promote biosimilars.
Stat News reported that Hahn did acknowledge the issue of high drug prices in response to questions from Senator Mike Braun, R-Indiana.
“Not a week goes by when I see a patient who doesn’t comment on the stress—‘financial toxicity’ is how people refer to it—of high prescription drug prices,” said Hahn, who said he supports “moving forward with action that makes sense.”
In addition, Hahn appeared noncommittal on the administration’s idea to allow certain drug imports from Canada. He did not commit to supporting individual importation proposal, but said he would be open to examining whether drug importation could be conducted safely.
Senator Lamar Alexander, R-Tennessee, the committee chairman, said a vote on the nomination is expected in early December.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.